Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
CORRESPONDENCE
Ahead of Print

First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor


1 Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
2 Department of Dermatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
3 Department of Radiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Correspondence Address:
Marco Siano,
Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen
Switzerland
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_50_18

Until recently, standard treatment for advanced melanoma comprised basically dacarbazine and interleukin-2, leading to low response rates and significant toxicity. These days, new treatments such as immunotherapy (anti-CTLA4 and anti-PD1 antibodies) and targeted therapy with BRAF/MEK-inhibitor combinations for patients harboring a BRAF mutation are available. In BRAF wild-type patients harboring an NRAS mutation, not fit for immunotherapy treatment options are still dismal. We describe an 84-year-old patient with widespread metastatic melanoma. He presented in July 2015 with a cerebral hemorrhage under anticoagulation for atrial fibrillation. Computed tomography revealed extensive metastatic disease (liver, lung, bones, lymph nodes, heart, and brain). Molecular testing was negative for BRAF but showed the presence of an NRAS mutation in exon 3 (pQ61K [c.181C>A]). The patient received as first-line treatment two cycles of cobimetinib showing a good partial remission and manageable side effects.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Bickel A
    -  Diem S
    -  Flatz L
    -  Stinn B
    -  Siano M
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed23    
    PDF Downloaded0    

Recommend this journal